AZD9291 in epidermal growth factor receptor inhibitor resistant non small cell lung cancer.
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in advanced EGFR mutant non small cell lung cancer have an objective response rate (ORR) of approximately 60 70% and a median progression free survival (PFS) of approximately 10 13 months. Studies of tumor biopsies performed after progression on EGFR TKI revealed that 50 60% of EGFR mutant NSCLC developed an EGFR exon 20 T790M mutation as a mechanism of acquired resistance. AZD9291 is a third generation irreversible EGFR TKI with activity against the activating EGFR mutation, the T790M acquired resistance mutation, and relative sparing of the wild type EGFR. AZD9291 was investigated in a phase I trial with expansion cohorts in patients with disease progression after EGFR TKI. Patients with and without detectable T790M mutations were enrolled in the trial. The ORR in patients with centrally confirmed and without detectable T790M mutations was 61% (95% CI, 52 70% and 21% (95% CI, 12 34% respectively. The PFS observed in patients with centrally confirmed and without detectable T790M mutations was 9.6 months (95% CI, 8.3 to not reached) and 2.8 months (95% CI, 2.1 4.3 months) respectively. At the dose for further investigation, 80 mg daily, the rate of all grade 3 5 drug related adverse events was 11% and the rates of grade 3 diarrhea and rash were 1% and 0% respectively. The identification of the T790M resistance mutation and the subsequent development of an agent against the mechanism of resistance provide a template for future drug development for acquired resistance to targeted therapy.
Translational lung cancer research